Electra Therapeutics (NASDAQ:ETRA) Director Orbimed Advisors Llc Buys 49,416 Shares of Company Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Orbimed Advisors Llc bought 49,416 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The shares were bought at an average price of $7.85 per share, with a total value of $387,915.60. Following the transaction, the director owned 5,230,578 shares of the company’s stock, valued at $41,060,037.30. The trade was a 0.95% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Orbimed Advisors Llc also recently made the following trade(s):

• On Tuesday, November 10th, Orbimed Advisors Llc purchased 22,700 shares of Electra Therapeutics stock. The shares were purchased at an average cost of $8.45 per share, with a total value of $191,815.00.
• On Monday, November 9th, Orbimed Advisors Llc bought 20,000 shares of Electra Therapeutics stock. The shares were purchased at an average price of $8.24 per share, with a total value of $164,800.00.
• On Thursday, November 5th, Orbimed Advisors Llc purchased 156,091 shares of Electra Therapeutics stock. The shares were acquired at an average cost of $7.31 per share, for a total transaction of $1,141,025.21.
• On Wednesday, November 4th, Orbimed Advisors Llc acquired 71,367 shares of Electra Therapeutics stock. The stock was bought at an average cost of $7.53 per share, with a total value of $537,393.51.
• On Tuesday, November 3rd, Orbimed Advisors Llc bought 245,113 shares of Electra Therapeutics stock. The stock was purchased at an average price of $7.86 per share, with a total value of $1,926,588.18.
• On Monday, September 21st, Orbimed Advisors Llc bought 1,333,333 shares of Electra Therapeutics stock. The shares were acquired at an average price of $15.00 per share, with a total value of $19,999,995.00.

Electra Therapeutics Stock Down 2.8%

NASDAQ ETRA opened at $7.99 on Wednesday. Electra Therapeutics, Inc. has a 12 month low of $6.86 and a 12 month high of $15.50.

Trending Headlines about Electra Therapeutics

Here are the key news stories impacting Electra Therapeutics this week:

• Positive Sentiment: Director Carl Gordon, through OrbiMed Advisors, reported purchases totaling 92,116 shares across November 6, 9 and 10, at prices ranging from $7.85 to $8.45 per share. Repeated buying by a director may signal confidence in the company, although it does not guarantee future performance. SEC ownership filing
• Neutral Sentiment: A report said short interest stood at zero shares as of November 10, with zero days to cover. That figure does not indicate meaningful reported short positioning, but it conflicts with the report’s description of a “significant increase,” making the short-interest update difficult to interpret.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ETRA shares. Zacks Research raised shares of Electra Therapeutics to a “hold” rating in a research report on Wednesday, October 14th. Wall Street Zen raised shares of Electra Therapeutics to a “hold” rating in a research report on Saturday, September 26th. JPMorgan Chase & Co. initiated coverage on shares of Electra Therapeutics in a research note on Thursday, October 22nd. They issued an “overweight” rating and a $36.00 target price for the company. Cantor Fitzgerald assumed coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They issued an “overweight” rating for the company. Finally, Evercore started coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Electra Therapeutics has an average rating of “Buy” and a consensus target price of $33.50.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.